lenalidomide has been researched along with Response Evaluation Criteria in Solid Tumors in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Falchook, G; Fu, S; Hong, DS; Janku, F; Kakadiaris, E; Kurzrock, R; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
1 trial(s) available for lenalidomide and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lenalidomide; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Response Evaluation Criteria in Solid Tumors; Thalidomide | 2016 |